Breast Cancer | Specialty

Integrating Palbociclib Into the Treatment of Breast Cancer

February 12th 2015

Preclinical and Clinical Evidence Supporting Palbociclib

February 12th 2015

SABCS Studies Highlight Promise and Complexity in Targeting PI3K in Breast Cancer

February 9th 2015

Although there is a significant scientific rationale for targeting the PI3K pathway in breast cancer, research findings presented recently at the 2014 San Antonio Breast Cancer Symposium (SABCS) highlight the inherent complexities in using agents directed at this cell-signaling network.

Latest News & Insight: February 5, 2015

February 6th 2015

Dr. Shih on Treating Lobular vs Ductal Breast Cancers

February 5th 2015

Jennifer Yuchen Shih, MD, a medical oncologist at Fox Chase Cancer Center, discusses the ABCSG-8 and BIG 1-98 studies and their impacts on the treatment of lobular breast cancer compared to ductal breast cancers.

Dr. Lori Goldstein on Neoadjuvant Treatment for HER2+ Breast Cancer

February 4th 2015

Lori Goldstein, MD, the director of the Naomi and Phil Lippincott Breast Evaluation Center, Fox Chase Cancer Center, discusses a neoadjuvant trial of lapatinib and trastuzumab with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer.

Dr. Germain on Scientific Rationale Behind Bortezomib/Fulvestrant for HR+ Breast Cancer

February 3rd 2015

Doris Germain, PhD, ‎associate professor at Mount Sinai Cancer Institute, discusses the scientific rationale behind a clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.

FDA Approves Palbociclib for Metastatic Breast Cancer

February 3rd 2015

The FDA has granted an accelerated approval to palbociclib as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

Dr. Denise Yardley on PI3K Inhibitors

January 29th 2015

Denise Yardley, MD, senior investigator, breast cancer research, Sarah Cannon Research Institute discusses the phase II FERGI study and how it can be applied to more than just breast cancer.

Dr. David Rimm on Immunofluorescence for HER2 Identification

January 26th 2015

David Rimm MD, PhD, professor of pathology and medicine, director of pathology tissue services, Yale University School of Medicine, explains the benefits of quantitativecfor the measurement of HER2 proteins.

Joan Lunden and Dr Patrick Borgen Discuss Imaging and Genetic Testing in Breast Cancer

January 23rd 2015

Joan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference.

Latest News & Insight: January 23, 2015

January 23rd 2015

Joan Lunden Discusses Her TNBC Diagnosis With Roy Firestone

January 22nd 2015

Joan Lunden discusses the diagnostic approach that led to the early detection of triple-negative breast cancer, which was undetected by mammogram and 3D mammogram but was detected with ultrasound.

Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer

January 22nd 2015

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.

Trastuzumab Regimen Lowers Recurrence Risk in Early-Stage, HER2-Positive Breast Cancer

January 20th 2015

Results of a phase II study showed that women with small, stage I HER2-positive tumors who received a combination of lower-intensity chemotherapy and the targeted drug trastuzumab following surgery were highly unlikely to have the cancer recur within 3 years.

Moving Beyond Targeted Therapy Stalwarts: Experts Weigh In on Four Tumor Types

January 19th 2015

OncologyLive asked experts in lymphoma, chronic myeloid leukemia, breast cancer, and non–small cell lung cancer to discuss the impact that the first targeted agents have had on these malignancies and the prospects for new therapeutic approaches.

BRCA Testing and Contralateral Prophylactic Mastectomy

January 13th 2015

Determination of BRCA1 and 2 mutation carrier status has become increasingly important. Estimates suggest that about 80% of breast cancers and 90% of ovarian cancers are sporadic; while only 5% to 10% of breast cancers are hereditary.

BRCA Pioneer Offit Shares Insights on Evolving Testing Landscape

January 7th 2015

For more than two decades, Kenneth Offit, MD, MPH, has been researching the molecular genetic factors that increase cancer risk, notably concerning germline BRCA mutations in breast and ovarian cancer, with a focus on potential preventive surgical remedies and screening programs for women at hereditary risk.

Dr. Arteaga on PI3K Pathway Inhibitors

January 6th 2015

Carlos Arteaga, MD, assistant director, Clinical Research, director, Breast Cancer program, Vanderbilt-Ingram Cancer Center, discusses the PI3K pathway and the role of therapeutic inhibitors in reducing the progression of breast cancer.

CTC Testing Offers Current Value and Future Promise in MBC

January 6th 2015

Circulating tumor cell (CTC) enumeration is a strong prognostic factor in metastatic breast cancer (MBC) and predicts treatment failure.